Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of Clinical MedicineOpen Access

The Use of JAK Inhibitors in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: A Narrative Review of Clinical and Real-World Evidence

View Full Paper
Ask AI
Bookmark
Share

Authors

GLGiuseppe LaulettaDCDaniele CecereLPLuca Potestio

Discussion

Loading...

Member takes

Overview

Narrative review identifies clinical challenges and benefits of JAK inhibitors in elderly patients, highlighting safety and efficacy.

Key Points

  • JAK inhibitors effectively treat moderate-to-severe atopic dermatitis in elderly patients with careful monitoring.
  • Abrocitinib showed efficacy in older patients similar to younger adults, but with higher adverse event rates.
  • Real-world evidence indicated sustainable clinical improvements with upadacitinib, particularly in hard-to-treat areas.
  • Age-specific guidance is essential, emphasizing the need for more dedicated studies in elderly populations.

Cite This Study

Lauletta et al. (2025) studied this question.

synapsesocial.com/papers/68c23d3ab210217d6478c5bbhttps://doi.org/10.3390/jcm14176327
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Use of JAK Inhibitors in AD Affecting Difficult-to-Treat Areas: Lessons from Real-Life2026
  2. 2Upadacitinib Leads in Efficacy: A Bayesian Network Meta‐Analysis of Four <scp>JAK</scp> Inhibitors in Moderate‐To‐Severe Atopic Dermatitis2026
  3. 3[Progress in the application of JAK inhibitors in atopic dermatitis].2025
  4. 4Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis2025
  5. 5Adverse effects of Janus kinase inhibitors with relevance for daily practice in dermatology2025 · 10 citations